DuPont (DD Quick QuoteDD - Free Report) declared that it will offer three newly approved bakery enzymes in Japan. The company recently secured approval of the Ministry of Health, Labor and Welfare for these enzymes for use as processing aids in that country.

 

Post the approval, bakers and flour millers will now include PowerFresh and PowerSoft enzymes in their bakery applications. This will help them to maintain the superior fresh-eating quality, improve softness and moistness in their products.

 

The PowerFresh and PowerSoft enzymes are based on proprietary G4 amylase technology which has anti-staling properties. This helps to improve and maintain bakery freshness throughout shelf life with better cost-in-use advantage.

 

The PowerFresh range will maintain the softness and provide extra resilience in breads. PowerFresh 3150 will be used for soft rolls and PowerFresh 4150 for sandwich breads. PowerSoft 7033 is expected to add sweetness to baked food and keep pound and sponge cakes moist.

 

DuPont has outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company’s shares have rallied 25.4% over this period, compared with the industry’s gain of around 21.6%.

 

DuPont is well placed to gain from its cost-cutting measures and new product launches. It has numerous products in its pipeline that are expected to contribute to the top-line growth.

 

Moreover, the proposed mega-merger with Dow Chemical (DOW Quick QuoteDOW - Free Report) is expected to deliver cost synergies of around $3 billion and growth synergies of roughly $1 billion. The companies expect the closing of the merger to take place in Aug 2017.

 

 

 

DuPont currently carries a Zacks Rank #2 (Buy).

 

Other top-ranked companies in the chemical space include Koninklijke DSM NV and The Chemours Company (CC Quick QuoteCC - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

 

Koninklijke has expected long-term growth of 7.7%.

 

Chemours has expected long-term growth of 15.5%.

 

 

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.                                                                                         

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>